PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsMERESTINIB
MERESTINIB
Merestinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase receptor UFO, receptor-type tyrosine-protein kinase FLT3, macrophage-stimulating protein receptor, tyrosine-protein kinase Mer, epithelial discoidin domain-containing receptor 1, tyrosine-protein kinase receptor Tie-1, hepatocyte growth factor receptor, and angiopoietin-1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8042———6
Biliary tract neoplasmsD001661—C24.911———2
Non-small-cell lung carcinomaD002289———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———3————3
Breast neoplasmsD001943EFO_0003869C502————2
Pancreatic neoplasmsD010190EFO_0003860C251————1
Colorectal neoplasmsD015179——1————1
Mantle-cell lymphomaD020522—C83.11————1
Myeloid leukemia acuteD015470—C92.01————1
Non-hodgkin lymphomaD008228—C85.91————1
CholangiocarcinomaD018281—C22.11————1
Gallbladder neoplasmsD005706EFO_0004606C231————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMERESTINIB
INNmerestinib
Description
Merestinib (LY2801653) is an experimental cancer drug in development by Eli Lilly. It is a small molecule inhibitor of MET and several other receptor tyrosine kinases such as MST1R, FLT3, AXL, MERTK, TEK, ROS1, NTRK1/2/3, and DDR1/2.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1
Identifiers
PDB—
CAS-ID1206799-15-6
RxCUI—
ChEMBL IDCHEMBL3545307
ChEBI ID—
PubChem CID44603533
DrugBankDB12381
UNII ID5OGS5K699E (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
AXL
AXL
FLT3
FLT3
MST1R
MST1R
MERTK
MERTK
DDR1
DDR1
TIE1
TIE1
MET
MET
TEK
TEK
Organism
Homo sapiens
Gene name
AXL
Gene synonyms
UFO
NCBI Gene ID
Protein name
tyrosine-protein kinase receptor UFO
Protein synonyms
AXL oncogene, AXL transforming sequence/gene
Uniprot ID
Mouse ortholog
Axl (26362)
tyrosine-protein kinase receptor UFO (Q80YQ3)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 343 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use